Extreme LDL-C concentration is associated with increased cardiovascular disease in women with homozygous familial hypercholesterolemia

被引:0
|
作者
Paquette, Martine [1 ]
Ruel, Isabelle [2 ]
Guay, Simon-Pierre [1 ,3 ]
Al-Baldawi, Zobaida [4 ]
Brisson, Diane [5 ]
Gaudet, Daniel [5 ]
Couture, Patrick [6 ]
Bergeron, Jean [6 ]
Hegele, Robert A. [7 ,8 ,9 ]
Francis, Gordon A. [10 ,11 ]
Sherman, Mark H. [12 ]
Mcpherson, Ruth [13 ,14 ]
Ransom, Thomas [15 ]
Brunham, Liam R. [10 ,11 ]
Mancini, John [16 ]
Mccrindle, Brian W. [17 ]
Latan, Lulia
Genest, Jacques [2 ]
Baass, Alexis [1 ,18 ,19 ]
机构
[1] Montreal Clin Res Inst, Lipids Nutr & Cardiovasc Prevent Clin, 110 Ave Des Pins Ouest, Montreal, PQ H2W1R7, Canada
[2] Res Inst McGill Univ Hlth Ctr, Montreal, PQ, Canada
[3] Univ Montreal, Dept Med, Div Endocrinol, Montreal, PQ, Canada
[4] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON, Canada
[5] ECOGENE 21 Clin & Translat Res Ctr, Chicoutimi, PQ, Canada
[6] Univ Laval, CHU Quebec, Dept Specialized Med, Lipid Clin, Quebec City, PQ, Canada
[7] Western Univ, Dept Med, Schulich Sch Med, London, ON, Canada
[8] Western Univ, Schulich Sch Med, Dept Biochem, London, ON, Canada
[9] Western Univ, Robarts Res Inst, London, ON, Canada
[10] Univ British Columbia, Ctr Heart Lung Innovat, Providence Hlth Care Res Inst, Vancouver, BC, Canada
[11] Univ British Columbia, Dept Med, Vancouver, BC, Canada
[12] McGill Univ, Hlth Ctr, Dept Endocrinol, Montreal, PQ, Canada
[13] Univ Ottawa, Heart Inst, Lipid Clin, Ottawa, ON, Canada
[14] Univ Ottawa, Heart Inst, Atherogenom Lab, Ottawa, ON, Canada
[15] Dalhousie Univ, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada
[16] Univ British Columbia, Ctr Cardiovasc Innovat, Vancouver, BC, Canada
[17] Univ Toronto, Hosp Sick Children, Labatt Family Heart Ctr, Dept Pediat, Toronto, ON, Canada
[18] McGill Univ, Div Expt Med, Dept Med, Montreal, PQ, Canada
[19] McGill Univ, Dept Med, Div Med Biochem, Montreal, PQ, Canada
关键词
Homozygous; Familial hypercholesterolemia; LDL-C; Cardiovascular; Risk factors; PREVALENCE;
D O I
10.1016/j.jacl.2024.10.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is arare genetic disease of low- density lipoprotein cholesterol (LDL-C) metabolism. Despite the devastating effect of this disease on atherosclerotic cardiovascular health, the disease phenotype and severity are more heterogeneous than previously thought. The predictors of atherosclerotic cardiovascular disease (ASCVD) in HoFH patients have never been systematically studied. OBJECTIVE: To investigate the univariate and multivariate predictors of ASCVD in HoFH patients. METHODS: Patients from the Canadian HoFH Registry were included in the present retrospective longitudinal study. Data for these patients were collected using a standardized questionnaire between 2019 and 2022 in 19 academic sites across Canada. Predictors of ASCVD were evaluated using Cox proportional hazards models. RESULTS: Among 48 HoFH patients, 26 (54%) of them had at least 1 ASCVD event. The average age at baseline was 19 +/- 15 years and women represented 56% of the cohort. The independent predictors of ASCVD events were male sex (HR 2.57 [1.13-5.84]), diabetes (HR 16.22 [3.38-77.97]), and LDL-C above the median of 14.45 mmol/L (559 mg/dL) (HR 3.10 [1.24-7.76]). When performing subgroup analysis according to sex, the presence of LDL-C above the median was associated with a significantly higher probability of ASCVD (88% vs 43%, P = .005) in women, but not in men (100% at age 40 in both groups, P = .98). CONCLUSION: This study reported for the first time the univariate and multivariate predictors of ASCVD in HoFH patients. We demonstrate that predictors of ASCVD in HoFH differ in males and females with respect to LDL-C levels. (c) 2024 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:105 / 113
页数:9
相关论文
共 50 条
  • [31] Protein changes in non-LDL-lipoproteins in familial hypercholesterolemia: implications in cardiovascular disease manifestation and outcome
    Badimon, Lina
    Padro, Teresa
    Cubedo, Judit
    CURRENT OPINION IN LIPIDOLOGY, 2017, 28 (05) : 427 - 433
  • [32] New metrics needed to visualize the long-term impact of early LDL-C lowering on the cardiovascular disease trajectory
    Packard, Chris J.
    Weintraub, William S.
    Laufs, Ulrich
    VASCULAR PHARMACOLOGY, 2015, 71 : 37 - 39
  • [33] The impact of SLCO1B1 rs4149056 on LDL-C target achievement after lipid lowering therapy optimization in men and women with familial hypercholesterolemia
    Bosco, Giosiana
    Barbagallo, Francesco Di Giacomo
    Di Marco, Maurizio
    Miano, Nicoletta
    Scilletta, Sabrina
    Spampinato, Salvatore
    Vitale, Alessio
    Di Bella, Federica
    Montalbano, Maria
    Di Mauro, Stefania
    Filippello, Agnese
    Scamporrino, Alessandra
    Milluzzo, Agostino
    Di Pino, Antonino
    Frittitta, Lucia
    Purrello, Francesco
    Piro, Salvatore
    Scicali, Roberto
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [34] PCSK9 R46L, Lower LDL, and Cardiovascular Disease Risk in Familial Hypercholesterolemia A Cross-Sectional Cohort Study
    Saavedra, Yascara Grisel Luna
    Dufour, Robert
    Davignon, Jean
    Baass, Alexis
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2014, 34 (12) : 2700 - 2705
  • [35] Cardiovascular disease risk in patients with elevated LDL-C levels: FH vs. non-FH
    Huang, Haomin
    Li, Lamei
    Yang, Anni
    Chen, Tao
    Shi, Ganwei
    Li, Feng
    Wang, Luya
    Cai, Gaojun
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [36] Higher LDL-C/HDL-C Ratio Is Associated with Elevated HbA1c and Decreased eGFR Levels and Cardiac Remodeling in Elderly with Hypercholesterolemia
    Li, Yufeng
    Li, Gang
    Laukkanen, Jari A.
    Wei, Linping
    Chen, Xinrui
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2024, 11 (05)
  • [37] Should patients with high cardiovascular risk and an LDL-C concentration below 70 mg/dl be treated with aggressive statin therapy?
    Lee, Cheol Whan
    Park, Seung-Jung
    CLINICAL LIPIDOLOGY, 2012, 7 (01) : 1 - 4
  • [38] PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients
    Leus, FR
    Zwart, M
    Kastelein, JJP
    Voorbij, HAM
    ATHEROSCLEROSIS, 2001, 154 (03) : 641 - 649
  • [39] Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study
    Alonso, Rodrigo
    Arroyo-Olivares, Raquel
    Diaz-Diaz, Jose Luis
    Fuentes-Jimenez, Francisco
    Arrieta, Francisco
    de Andres, Raimundo
    Gonzalez-Bustos, Pablo
    Argueso, Rosa
    Martin-Ordiales, Mercedes
    Martinez-Faedoj, Ceferino
    Illank, Fatima
    Saenz, Pedro
    Donate, Jose Maria
    Munoz-Torrero, Juan F. Sanchez
    Martinez-Hervas, Sergio
    Mata, Pedro
    ATHEROSCLEROSIS, 2024, 393
  • [40] LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia
    Bogsrud, Martin P.
    Graesdal, Asgeir
    Johansen, Dan
    Langslet, Gisle
    Hovland, Anders
    Arnesen, Kjell-Erik
    Mundal, Liv J.
    Retterstol, Kjetil
    Wium, Cecilie
    Holven, Kirsten B.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2019, 13 (02) : 279 - 286